-
ArticlePublication 2008Potential Cost-Effectiveness of Vaccination against Herpes Zoster and Post-Herpetic Neuralgia
This 2008 Canadian study assessed the cost effectiveness of the Zoster Vaccine Live (ZVL) vaccine …
This 2008 Canadian study assessed the cost effectiveness of the Zoster Vaccine Live (ZVL) vaccine against herpes zoster (HZ) and post-herpetic neuralgia (PHN). The authors used a cohort model to estimate the burden of HZ and the cost-effectiveness of HZ vaccination from a ministry of health perspective using Canadian population-based data. They examined different ages at vaccination and conducted probabilistic sensitivity analysis.There are about 130,000 new cases of HZ, 17,000 cases of PHN and 20 deaths…
North America | Cost-Effectiveness Analysis | Preferences/Values | Dynamic Transmission | Infectious Diseases | Health/Medicine -
GuidelinesPublication 2016Decision Models in Clinical Preventive Services Recommendations
The U.S. Preventive Services Task Force (USPSTF) develops evidence-based recommendations about preventive care based on …
The U.S. Preventive Services Task Force (USPSTF) develops evidence-based recommendations about preventive care based on comprehensive systematic reviews of the best available evidence. Decision models provide a complementary, quantitative approach to support the USPSTF as it deliberates about the evidence and develops recommendations for clinical and policy use. This article describes the rationale for using modeling, an approach to selecting topics for modeling, and how modeling may inform recommendations about clinical preventive services.
North America | Decision Analysis | Health Outcomes | Evidence Synthesis | Mathematical Models | Health Systems | Policy/Regulation | Health/Medicine -
ArticlePublication 2015Cost-Effectiveness of Herpes Zoster Vaccine for Persons Aged 50 Years
This article reports on a cost-effectiveness analysis of the original herpes zoster (HZ) vaccine (ZVL) …
This article reports on a cost-effectiveness analysis of the original herpes zoster (HZ) vaccine (ZVL) that at the time of this study was approved for persons age 50+. The authors used a Markov model to simulate adults aged 50 years over a lifetime from a societal perspective; outcomes included the number of HZ and postherpetic neuralgia (PHN) cases prevented and the incremental cost per quality-adjusted life-year (QALY) saved. Their focus was on the cost effectiveness…
North America | Cost-Effectiveness Analysis | State-Transition | Infectious Diseases | Health Systems | Health/Medicine -
ReviewPublication 2013Systematic Review of the Cost Effectiveness of Herpes Zoster Vaccination
This review summarized the herpes zoster (HZ) vaccination cost effectiveness literature, consisting of 11 studies …
This review summarized the herpes zoster (HZ) vaccination cost effectiveness literature, consisting of 11 studies Most studies evaluated the cost effectiveness of universal HZ vaccination in adults aged 50 years or 60 years and older and all studies calculated costs per QALY. The costs per QALY gained and the incremental cost-effectiveness ratio (ICER) differed depending on the age at vaccination, duration of vaccine efficacy, cost of vaccine course, and economic perspective. All but one of…
North America | Cost-Effectiveness Analysis | Preferences/Values | Infectious Diseases | Clinical Care | Economics/Finance | Health/Medicine -
Working PaperPublication 2017Cost-Effectiveness Analysis of Adjuvanted Subunit Vaccine for Prevention of Herpes Zoster
Herpes zoster (HZ) develops in up to 50% of unvaccinated individuals who live to 85 …
Herpes zoster (HZ) develops in up to 50% of unvaccinated individuals who live to 85 years of age, accounting for more than 1 million cases of HZ annually in the United States. A live attenuated vaccine (LAV) for HZ is U.S. FDA approved for persons 50 years or older, though CDC Advisory Committee on Immunization Practices (ACIP) recommendations are only for persons beginning at age 60 years. LAV efficacy at preventing HZ is ~70% for…
North America | Cost-Effectiveness Analysis | Mathematical Models | Infectious Diseases | Economics/Finance | Health/Medicine
5 Shown
Teaching Resources
Collections
Format
Learner Level
Teaching Topic